docetaxel + oxaliplatin + S-1

The combination of docetaxel, oxaliplatin, and S-1 (commonly referred to as the DOS regimen) is a multi-agent chemotherapy protocol primarily investigated for the treatment of advanced gastric cancer and adenocarcinoma of the esophagogastric junction. - **Docetaxel** is a taxane-class antineoplastic agent that promotes microtubule assembly while inhibiting their disassembly, thereby disrupting mitotic cell division. - **Oxaliplatin** is a platinum-based chemotherapeutic that induces cytotoxicity mainly through DNA crosslinking (both intrastrand and interstrand), which inhibits DNA replication and transcription[6]. - **S-1** is an oral fluoropyrimidine derivative combining tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU bioavailability), and oteracil (to reduce gastrointestinal toxicity). It acts as an antimetabolite interfering with DNA synthesis. This combination has been studied in neoadjuvant settings—administered before surgery—to improve pathological response rates, progression-free survival, and overall survival in patients with large type 3 or type 4 gastric cancers or esophagogastric junction adenocarcinomas[1][2][3][4]. The regimen typically involves three cycles every three weeks prior to surgical resection.

Other names

docetaxel + oxaliplatin + S-1DOS regimenDOS therapy